Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CEL SCI CORPCVM · Entity 7495 | Senior Vice President | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CEL SCI CORP
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2036-08-13 | Direct | 118,010 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 80,000 · Balance 118,010 F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 13:33 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 80,000 | $0.01 Strike: $1.49 | $800.00 |
DisclosureSEC source: 0001282304-26-000001 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,010 Underlying: Common Stock · 80,000 shares Expires 2036-08-13 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 21:12 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 7,500 | $0.01 Strike: $8.20 | $75.00 |
DisclosureSEC source: 0001236030-25-000012 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,008 Underlying: Common Stock · 7,500 shares Expires 2035-07-27 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:40 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 65,000 | $0.01 Strike: $1.36 | $650.00 |
DisclosureSEC source: 0001236030-23-000010 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 917,027 Underlying: Common Stock · 65,000 shares Expires 2033-08-07 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 21:21 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 65,000 | $0.01 Strike: $3.35 | $650.00 |
DisclosureSEC source: 0001236030-22-000012 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,927 Underlying: Common Stock · 65,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:33 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000015 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,827 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:22 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 130,000 | $0.01 Strike: $20.61 | $1,300.00 |
DisclosureSEC source: 0001236215-21-000006 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,827 Underlying: Common Stock · 130,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 21:16 UTC | CEL SCI CORP CVM · Entity 7495 | SaleCommon Stock | 10,000 | $24.38 | $243,793.00 |
DisclosureSEC source: 0001282304-21-000003 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,108 Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:49 UTC | CEL SCI CORP CVM · Entity 7495 | SaleCommon Stock | 10,000 | $12.73 | $127,290.00 |
DisclosureSEC source: 0001236031-20-000033 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,108 Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:52 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 160,000 | $0.01 Strike: $10.93 | $1,600.00 |
DisclosureSEC source: 0001236031-20-000019 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,027 Underlying: Common Stock · 160,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:02 UTC | CEL SCI CORP CVM · Entity 7495 | SaleCommon Stock | 8,000 | $8.69 | $69,559.20 |
DisclosureSEC source: 0001236031-19-000026 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,108 Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 21:14 UTC | CEL SCI CORP CVM · Entity 7495 | SaleCommon Stock | 8,000 | $7.03 | $56,208.00 |
DisclosureSEC source: 0001236031-19-000022 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,108 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:06 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 2,915 | $6.86 | $19,996.90 |
DisclosureSEC source: 0001236031-19-000017 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,108 Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:51 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 206,880 | $0.01 Strike: $5.65 | $2,068.80 |
DisclosureSEC source: 0001236031-19-000011 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,427 Underlying: Common Stock · 206,880 shares Expires 2029-04-10 F1 · shares: Part of the options were awarded in recognition of the salary that has been deferred over an approximate 12 month period and not paid in cash. These options awarded are equal to 0.25 option for every dollar deferred. F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 18:22 UTC | CEL SCI CORP CVM · Entity 7495 | GrantCommon Stock | 48,193 | $0.83 | $40,000.19 |
DisclosureSEC source: 0001236031-18-000035 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,193 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:46 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 135,000 | $0.01 Strike: $2.45 | $1,350.00 |
DisclosureSEC source: 0001236031-18-000020 · primary_doc.xml · derivative · entry 2 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,547 Underlying: Common Stock · 135,000 shares Expires 2028-04-30 F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:46 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 13,347 | $0.01 Strike: $2.45 | $133.47 |
DisclosureSEC source: 0001236031-18-000020 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,547 Underlying: Common Stock · 13,347 shares Expires 2028-04-30 F1 · shares: The options were awarded in recognition of the salary that has been deferred over the last 18 months and not paid in cash. The options awarded are equal to 0.25 option for every dollar deferred. F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 21:25 UTC | CEL SCI CORP CVM · Entity 7495 | SaleCommon Stock | 17,109 | $2.52 | $43,114.68 |
DisclosureSEC source: 0001236031-17-000019 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · shares: Shares were sold to pay for the taxes owed on the incentive stock bonus shares recently received that were approved by the shareholders at the 2014 Annual Shareholder Meeting. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 13:31 UTC | CEL SCI CORP cvm · Entity 7495 | GrantOptions · Derivative | 90,000 | $0.01 Strike: $2.18 | $900.00 |
DisclosureSEC source: 0001236031-17-000015 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,800 Underlying: Common Stock · 90,000 shares Expires 2027-07-27 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.